Cristina Larkin

Cristina Larkin is a declared insider of Spero Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 6 November 2017 to 1 February 2022, the count stands at 7 filings.

In open-market terms, that means 1 purchase worth €18k on one side and 2 sales worth €247k on the other. Sales outweigh purchases by €229k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 share grants and 2 option exercises.

The newest entry dates from 3 February 2022: a share grant, in Spero Therapeutics, Inc. The last insider purchase was made public on 7 November 2017, 3,289 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.